Radius Health (RDUS) Reaches $26.72 52-Week Low; National Oilwell Varco (NOV) Shorts Lowered By 0.88%

November 14, 2017 - By Adrian Mccoy

The stock of Radius Health Inc (NASDAQ:RDUS) hit a new 52-week low and has $25.65 target or 4.00% below today’s $26.72 share price. The 6 months bearish chart indicates high risk for the $1.19B company.

The 1-year low was reported on Nov, 14 by Barchart.com. If the $25.65 price target is reached, the company will be worth $47.60M less. About 100,946 shares traded. Radius Health Inc (NASDAQ:RDUS) has risen 9.02% since November 14, 2016 and is uptrending. It has underperformed by 7.68% the S&P500.

National Oilwell Varco Incorporated (NYSE:NOV) had a decrease of 0.88% in short interest. NOV’s SI was 30.74M shares in November as released by FINRA. Its down 0.88% from 31.01 million shares previously. With 3.47 million avg volume, 9 days are for National Oilwell Varco Incorporated (NYSE:NOV)’s short sellers to cover NOV’s short positions. About 183,662 shares traded. National-Oilwell Varco, Inc. (NYSE:NOV) has risen 11.97% since November 14, 2016 and is uptrending. It has underperformed by 4.73% the S&P500.

Among 34 analysts covering National Oilwell Varco (NYSE:NOV), 10 have Buy rating, 6 Sell and 18 Hold. Therefore 29% are positive. National Oilwell Varco had 103 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of National-Oilwell Varco, Inc. (NYSE:NOV) has “Hold” rating given on Friday, October 6 by Cowen & Co. Cowen & Co maintained the stock with “Market Perform” rating in Thursday, February 4 report. The firm has “Hold” rating by Jefferies given on Monday, July 11. Jefferies maintained National-Oilwell Varco, Inc. (NYSE:NOV) rating on Thursday, October 5. Jefferies has “Hold” rating and $34.0 target. The rating was maintained by Cowen & Co on Friday, April 29 with “Market Perform”. The rating was maintained by BMO Capital Markets on Wednesday, October 11 with “Sell”. The company was maintained on Tuesday, September 5 by BMO Capital Markets. The rating was downgraded by Barclays Capital on Wednesday, April 20 to “Equal-Weight”. The stock has “Underperform” rating by Credit Suisse on Friday, September 4. The company was maintained on Friday, June 2 by RBC Capital Markets.

Investors sentiment decreased to 0.67 in Q2 2017. Its down 0.30, from 0.97 in 2017Q1. It is negative, as 82 investors sold National-Oilwell Varco, Inc. shares while 216 reduced holdings. 50 funds opened positions while 151 raised stakes. 340.10 million shares or 1.18% less from 344.17 million shares in 2017Q1 were reported. Tcw Gp holds 0% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV) for 12,809 shares. Ww Asset invested 0.04% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). American Natl Insurance Communications Tx has 0.12% invested in National-Oilwell Varco, Inc. (NYSE:NOV) for 68,255 shares. Commerzbank Aktiengesellschaft Fi holds 27,535 shares or 0.02% of its portfolio. Wesbanco Bancorp stated it has 0.01% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). Academy Capital Tx, a Texas-based fund reported 546,234 shares. Advantus Capital Mgmt Inc invested in 0.03% or 38,160 shares. Dalton Greiner Hartman Maher And stated it has 0.76% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). Dodge And Cox reported 31.34M shares stake. 31,076 are owned by Gateway Investment Advisers Ltd Limited Liability Company. Nomura Asset Mngmt Co Ltd stated it has 0.1% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). Hutchinson Capital Mngmt Ca has invested 5.12% of its portfolio in National-Oilwell Varco, Inc. (NYSE:NOV). Dekabank Deutsche Girozentrale holds 0.03% or 121,474 shares. Geode Cap Mngmt Limited Liability invested in 0.05% or 3.78M shares. Ls Investment Advisors Lc owns 0.04% invested in National-Oilwell Varco, Inc. (NYSE:NOV) for 18,186 shares.

National Oilwell Varco, Inc. is an oilfield equipment maker and technology provider. The company has market cap of $12.35 billion. The Firm operates through four divisions: Rig Systems, Rig Aftermarket, Wellbore Technologies and Completion & Production Solutions. It currently has negative earnings. The Rig Systems segment makes and supports the capital equipment and integrated systems needed to drill gas and oil wells on land and offshore.

Since May 16, 2017, it had 2 buys, and 0 insider sales for $2.82 million activity. On Thursday, May 25 the insider BIOTECH GROWTH N V bought $1.45 million.

Investors sentiment increased to 1.42 in 2017 Q2. Its up 0.43, from 0.99 in 2017Q1. It is positive, as 26 investors sold Radius Health Inc shares while 29 reduced holdings. 30 funds opened positions while 48 raised stakes. 47.13 million shares or 10.56% more from 42.63 million shares in 2017Q1 were reported. Envestnet Asset Mgmt holds 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 3,915 shares. Amer Gru holds 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 23,083 shares. Da Davidson And holds 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 200 shares. New York-based Perceptive Advsrs Limited Liability Corporation has invested 1.47% in Radius Health Inc (NASDAQ:RDUS). Wells Fargo And Co Mn holds 0% or 61,407 shares in its portfolio. Bain Cap Pub Equity Mngmt Ltd has invested 1.25% in Radius Health Inc (NASDAQ:RDUS). Tower Research Capital Ltd Liability Company (Trc) has invested 0% in Radius Health Inc (NASDAQ:RDUS). Loring Wolcott & Coolidge Fiduciary Advsrs Llp Ma holds 10 shares. Bb Biotech Ag invested in 5.04 million shares. Salzhauer Michael holds 0.16% or 7,500 shares. 150 are held by Next Group Incorporated. Camber Management Limited Liability Corporation accumulated 100,000 shares. Goldman Sachs Grp Inc invested 0% of its portfolio in Radius Health Inc (NASDAQ:RDUS). Huntington State Bank holds 430 shares. Schwab Charles Inv Management owns 140,895 shares for 0.01% of their portfolio.

Radius Health, Inc. is a biopharmaceutical company. The company has market cap of $1.19 billion. The Firm is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. It currently has negative earnings. The Company’s lead investigational product candidate, TYMLOS injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Among 9 analysts covering Radius Health (NASDAQ:RDUS), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Radius Health had 25 analyst reports since August 7, 2015 according to SRatingsIntel. As per Monday, June 5, the company rating was maintained by Canaccord Genuity. The stock of Radius Health Inc (NASDAQ:RDUS) has “Buy” rating given on Wednesday, September 21 by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald on Sunday, June 4 with “Buy”. The firm earned “Hold” rating on Wednesday, February 24 by Jefferies. The stock of Radius Health Inc (NASDAQ:RDUS) earned “Buy” rating by H.C. Wainwright on Friday, March 24. Jefferies maintained the stock with “Hold” rating in Tuesday, October 10 report. Jefferies maintained Radius Health Inc (NASDAQ:RDUS) on Monday, September 4 with “Hold” rating. The stock of Radius Health Inc (NASDAQ:RDUS) has “Hold” rating given on Monday, June 5 by Jefferies. The rating was maintained by Cantor Fitzgerald with “Buy” on Sunday, July 23. The company was maintained on Monday, September 25 by Cantor Fitzgerald.

By

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>